Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone capsules for radiation-induced lung injury with or without immune-related pneumonitis
CTR20260078Phase 2Active
- Sponsor
- Gyre Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in radiation-induced lung injury (RILI), alveolitis, sponsored by Gyre Pharmaceuticals. Started Apr 2026; status: active.
02
Drugs
pirfenidone
03
Conditions
radiation-induced lung injury (RILI)alveolitis
Beyond the preview
Go deeper on CTR20260078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260078.